The International Tennis Integrity Agency (ITIA) today confirms that Parikshit Somani, a 25-year-old tennis player from India, has been provisionally suspended under the Tennis Anti-Doping Programme (TADP).
The ITIA sent the player a pre-charge notice of an Anti-Doping Rule Violation on 23 September 2025 under Article 2.1 of the TADP (presence of a Prohibited Substance in a Player’s Sample) and/or Article 2.2 (Use of a Prohibited Substance without a valid Therapeutic Use Exemption (TUE)).
Somani, who reached a career-high world doubles ranking of 256 in July 2025, provided an in-competition sample while competing in an ATP Challenger event in Astana, Kazakhstan, on 31 July 2025.
The sample was split into A and B samples and the subsequent analysis found that the A sample contained trimetazidine, which is prohibited under the TADP, in the category of Hormone and Metabolic Modulators (section S4.4 of the 2025 World Anti-Doping Agency Prohibited List).
Trimetazidine is a non-Specified substance. Findings for non-Specified Substances carry a mandatory provisional suspension – in Somani’s case, this has been in effect from 23 September 2025. Players have the right to appeal the imposition of their provisional suspension before an independent tribunal chair. To date, Somani has not appealed.
While provisionally suspended, Somani is prohibited from playing in, coaching at, or attending any tennis event authorised or sanctioned by the members of the ITIA (ATP, ITF, WTA, Tennis Australia, Fédération Française de Tennis, Wimbledon and USTA) or any national association.
The ITIA is an independent body established by its tennis members to promote, encourage, enhance, and safeguard the integrity of their professional tennis events.
Ends
Published 09 October 2025 13:00
